Category Archives: News

BioCurate Project awarded subsidy by the National Drug Discovery Centre

BioCurate Project awarded subsidy by the National Drug Discovery Centre

Author

Date

BioCurate

February 14, 2020

We are pleased to announce Dr Lorna Mitchell, Director of Small Molecule Therapeutics at BioCurate, has been named one of the four recipients of an Australian Government subsidy supporting screening activities at the National Drug Discovery Centre (NDDC).

Dr Lorna Mitchell is leading a BioCurate and Monash University team to investigate new medicines for the treatment of blood cancers including Burkitt’s lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM).

The NDDC provides researchers in Australia with access to the latest in advanced robotic high-throughput screening to ensure patients will benefit from novel treatments sooner.

The subsidy covers 90 per cent of the cost of using the NDDC, reducing the cost of a traditional screening campaign – normally upwards of $300,000 – to around $30,000-$45,000.

Congratulations to Dr Lorna Mitchell and the project team for this latest accomplishment.

Find out more about the four projects awarded subsidies.

Visit the National Drug Discovery Centre website for more information.

Return to News
Share

2019 Annual Report

2019 Annual Report

Author

Date

BioCurate

March 30, 2020

Annual Report for the year ended 31 December 2019.

The 2019 Annual Report focuses on BioCurate’s significant progress with the company’s principal business – building BioCurate’s portfolio and a long-term project pipeline, and improving the understanding of research translation.

BioCurate 2019 Annual Report

 

Return to News
Share

Bridging the valley of death

Bridging the valley of death

Author

Date

BioCurate

February 14, 2020

John Brumby discusses BioCurate and the challenge of commercialisation with Innovation Intelligence. The following is an excerpt from Innovation Intelligence's upcoming book: Australia’s Nobel Laureates Vol. III: State of Our Innovation Nation 2020 and Beyond, taking a whole of economy health check of Australia’s innovation ecosystem.

When I was a young backbencher in the Hawke Government, one of the people I admired and learned from was the Minister for Science, Barry Jones. Barry had written the globally influential book Sleepers, Wake! in which he warned that ‘technologically based transitions create revolutionary economic and social changes.’ He called on governments to shape the future for the better through smart responses to technological change. To his credit, Barry Jones pushed the Hawke Government to invest a lot more in science, R&D and technology. He secured some wins, including a $1m National Biotechnology Program. Barry once told me, however, that he had a recurring nightmare. He worried that after all our efforts and all our investments, we would look back in years to come and find that Australian scientific research had not moved far along the path from the laboratory to the market. If this happened then our research would have failed to make its maximum possible impact in the world.

I’m afraid to say these fears came true. Australia can be proud of our scientific achievements, especially in medical research. But an ongoing frustration is that too little of it makes the long journey to market. Too much is lost in the ‘valley of death’ before it can even reach the clinical trial stage. And if it doesn’t reach clinical trial, it can’t reach patients. BioCurate was set up to address this problem, and has already become an important part of Australia’s innovation ecosystem.

BioCurate came about thanks to an unprecedented partnership between the Vice Chancellors of Victoria’s two biggest universities: Monash University and the University of Melbourne. It was the first time two universities of this size, in such close proximity to one another (making them competitors) had come together in this way. Both Vice Chancellors recognised that their universities were sitting on a gold mine. Melbourne and Monash receive about $100m per annum each in government funding for medical research, and both are in the top 100 universities in the world for research output. But the Vice Chancellors also realised that the right settings were not in place to make good on the promise of this research—to get it to the bedsides of the patients that need it. They decided to put their money where their mouths were. Each university invested $25m, and the Victorian Government invested another $10m. BioCurate was launched in 2016, and I was proud to come on board as Chair. In 2017 we were delighted to appoint distinguished haematologist and oncologist Dr Glenn Begley as BioCurate’s inaugural CEO.

Read the entire essay on Innovation Intelligence’s website

Return to News
Share

Takeda Pharmaceuticals and BioCurate announce collaboration to accelerate innovative early stage discoveries of new therapeutics and drugs

Takeda Pharmaceuticals and BioCurate announce collaboration to accelerate innovative early stage discoveries of new therapeutics and drugs

Author

Date

BioCurate

October 30, 2019

BioCurate, a joint venture between Monash University and The University of Melbourne with support from the Victorian State Government, has signed an agreement with Takeda Pharmaceutical Company Limited (Takeda) to share commercial and scientific expertise with the aim of accelerating the discovery and development of new therapeutics and drugs.

Takeda and BioCurate will collaborate directly and via participation in BioCurate’s Industry and Scientific Advisory Committee to assess new therapeutic candidates arising from BioCurate’s academic partners.

BioCurate was established with a specific focus to fast-track research discoveries into early therapeutic development by addressing the barriers that limit the translation and commercialisation of early-stage research. The company’s goal is to build a sustainable capability in drug development, which entails nurturing projects to be attractive to potential investors or commercial partners. Collaborations such as this ensure promising projects receive critical expert advice and commercial assessment throughout the drug discovery process, thereby streamlining the therapeutic development process.

“BioCurate is very pleased to expand our collaborative linkages with experts who are able to provide invaluable scientific advice, commercial insight and partnering opportunities to BioCurate and Australia’s wider medical research sector,” said Dr C. Glenn Begley, CEO of BioCurate.

Takeda has a unique approach to collaboration that leverages diverse partnership models to unlock the best science no matter where it resides and to translate into life-changing medicines for patients. Each of its partnerships is created with aligned incentives, designed to leverage what each partner does best across academia and industry. Takeda has more than 200 active partnerships, and through its Center for External Innovation, has more than 25 new company creations and 45 venture financings since 2016.

We look forward to applying the expertise of Takeda’s world-class R&D engine, which spans from target identification through clinical development and commercialization, to our collaboration with BioCurate,” said Steve Hitchcock, Head, Research at Takeda. “Together we will help identify and nurture the discoveries from BioCurate’s ecosystem that have the greatest potential to become transformational new therapies for patients in need.”

Conducive to this broad-based collaboration is Australia’s ‘Parkville Precinct.’ This cluster of 30 world-class hospitals, research institutes, teaching and biotech organisations in Melbourne employs approximately 10,000 researchers, many of whom are the global leaders in their field. With its headquarters embedded within this precinct, BioCurate’s internationally-experienced team is well-placed to take part in and contribute to this thriving research ecosystem.

ENDS

 


 

About BioCurate

BioCurate Pty Ltd was formed jointly in June 2016 by The University of Melbourne and Monash University, with support from the Victorian State Government to accelerate early phases of new drug development. BioCurate is seeking to address the key challenges in early stage drug development and to increase the number, quality and rate of translation of new drug discoveries into medically sound projects that are attractive for investment via commercial or public-good routes. The Company’s vision is to be a recognised global leader in the translation of basic medical research into human therapeutics. BioCurate is one of the key partners in the Biomedical Translation Bridge Program, a national initiative of the Australian Government aimed at nurturing the translation of new therapies, technologies and medical devices through to the proof of concept stage.  www.biocurate.com

 


 

Media contact

Linda Peterson – l.peterson@biocurate.com – Tel: +61 419 320 435

 

Return to News
Share

Gilead and BioCurate work together to develop ‘Industry-Ready’ therapeutic projects

Gilead and BioCurate work together to develop ‘Industry-Ready’ therapeutic projects

Author

Date

BioCurate

October 17, 2019

Gilead Sciences, Inc and BioCurate Pty Ltd agree to collaborate with the aim of increasing the quality and quantity of ‘industry-ready’ therapeutic projects.

BioCurate is very pleased to advise that it continues to build on its commitment to engage with major international industry partners with the recent signing of a Memorandum of Understanding with Gilead Sciences, Inc (Gilead).

Gilead is a research-based biopharmaceutical company that discovers, develops and commercialises innovative medicines in areas of unmet medical need, with operations in more than 35 countries world-wide.

This commitment will help ensure BioCurate’s new drug development programs are informed and aligned with addressing unmet patient and market needs, and provide potential future partnering opportunities.

The principles underpinning this collaboration are consistent with those BioCurate has already in place with other industry partners: i.e. a non-exclusive arrangement with the aim of increasing the quality and quantity of ‘industry-ready’ therapeutic projects emanating principally from the University of Melbourne and Monash University.

 

Return to News
Share

Servier Australia & BioCurate strike an agreement to collaborate and accelerate discoveries of new therapeutics and drugs

Servier Australia & BioCurate strike an agreement to collaborate and accelerate discoveries of new therapeutics and drugs

Author

Date

BioCurate

July 16, 2019

Australia, in particular the state of Victoria, is internationally recognised for its excellence in biomedical research. This provides a compelling opportunity for drug discovery and biomedical science translation.

Servier and BioCurate will collaborate under the terms of a memorandum of understanding (MOU), whereby they will work together, both directly and via participation in BioCurate’s Industry and Scientific Advisory Committee, in providing advice and assessing new therapeutic candidates arising from BioCurate’s academic partners.

BioCurate was established with a specific focus on addressing the barriers that limit the translation and commercialisation of early stage research. With the aim of increasing the number of ‘investment-ready’ projects, BioCurate is committed to engaging closely and collaboratively with industry and other potential investors to ensure promising projects receive critical expert advice and assessment throughout the drug discovery process.

“BioCurate is very pleased to receive this further endorsement from industry and to be expanding our collaborative linkages with experts who are able to provide invaluable scientific advice, commercial insight and partnering opportunities to BioCurate and Australia’s wider medical research sector,” said Dr C. Glenn Begley, CEO of BioCurate.

Australia is a leading country in scientific research and development (R&D), with a strong reputation in invention and innovation in both medical research and improving healthcare. To capture the opportunities of prolific R&D ecosystems, such as Australia, and to further strengthen its pipeline, the Servier International Center of Therapeutic Research has actively engaged some of the best researchers worldwide.

“Collaboration with biotech companies, academia, institutes and government is a key cornerstone of our strategy to put the patient and innovation first,” highlighted Claude Bertrand, Executive Vice-President Research & Development at Servier.

Conducive to this broad-based collaboration is Australia’s ‘Parkville Precinct.’ This cluster of 30 world-class hospitals, research institutes, teaching and biotech organisations in Melbourne employs approximately 10,000 researchers, many of whom are the global leaders in their field. With its headquarters embedded within this precinct, BioCurate’s internationally-experienced team is well-placed to complement this thriving research ecosystem.

“BioCurate is very proud of the industry-experienced team it is building and making available to the local sector. This is unique in the Australian context. Our staff are solely focused on increasing the clinical impact from medical research and we are doing this by sharing our hands-on experience, knowledge and networks from working in industry both internationally and in Australia,” Dr Begley said.

Servier is one of the first pharmaceutical companies to sign an agreement with BioCurate to share expertise and accelerate discoveries of new drugs.

“We are excited by the opportunity to create synergies between Servier’s scientific expertise and capabilities and BioCurate’s know-how in improving the quality of early stage research for a successful translation into therapeutic solutions for the benefit of patients,” concluded Pedro Crisanto, Director Servier International Centre for Therapeutic Research Australia & New Zealand. “Australia has ranked 5th in the Scientific American Worldwide scorecard 3 years running. Alongside BioCurate, Servier aims to translate this exciting science into improved health outcomes for patients around the world.”

 


 

About Servier

Servier is an international pharmaceutical laboratory run by a Foundation, with its headquarters in Suresnes in France. With a solid international footing in 149 countries and revenues of €4.2 billion in 2018, Servier employs 22 000 people around the globe. Wholly independent, the Group reinvests 25% of its income (excluding generics) into Research and Development and ploughs all its profit into its growth. The Group attributes its growth to an incessant quest for innovation in five fields of excellence: cardiovascular diseases, immune-mediated inflammatory diseases, neurodegenerative diseases, cancers and diabetes, as well as its development of high-quality generics. Servier also offers e-health solutions in addition to its medicinal products. www.servier.com

Servier has been present in Australia since 1979 through Servier Australia, the local subsidiary, and through the International Centre for Therapeutic Research (ICTR) launched in 1999. www.servier.com.au

Follow us:  LinkedIn  Facebook  Twitter

 


 

About BioCurate

BioCurate Pty Ltd was formed jointly in June 2016 by The University of Melbourne and Monash University, with support from the Victorian State Government to accelerate early phases of new drug development. BioCurate is seeking to address the key challenges in early stage drug development and to increase the number, quality and rate of translation of new drug discoveries into medically sound projects that are attractive for investment via commercial or public-good routes. The Company’s vision is to be a recognised global leader in the translation of basic medical research into human therapeutics. BioCurate is one of the key partners in the Biomedical Translation Bridge Program, a national initiative of the Australian Government aimed at nurturing the translation of new therapies, technologies and medical devices through to the proof of concept stage.

Follow us: LinkedIn Twitter

 


 

Media contacts

Servier
Sonia Marques – sonia.marques@servier.com
Tel. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13

BioCurate
Linda Peterson – l.peterson@biocurate.com
Tel: +61 419 320 435

 

Return to News
Share

CCRM Australia and BioCurate enter into a MoU to accelerate the translation of therapies in the Australian regenerative medicine sector

CCRM Australia and BioCurate enter into a MoU to accelerate the translation of therapies in the Australian regenerative medicine sector

Author

Date

BioCurate

June 26, 2019

The Centre for Commercialization of Regenerative Medicine Australia (CCRM Australia) is proud to collaborate with BioCurate to advance the translation and commercialisation of life changing therapies in the Australian regenerative medicine sector.

Australia has a vibrant and world-class regenerative medicine eco-system and is internationally recognised for its discovery and translational research.  However, the developmental path of promising regenerative medicines is often fragmented, opportunistic and ad hoc. The commercially relevant skill set and dedicated financial capital of CCRM and BioCurate are critical resources available to assist researchers and startups navigate this challenging development path.

This MoU lays the foundation for collaboration between CCRM Australia and BioCurate. The scope promotes identification of suitable projects that parties can contribute towards by leveraging their expertise, networks and financial resources with the goal of joint translation of regenerative medicine in its broadest definition, i.e. harness the power of cellular and gene therapies to treat, repair, regenerate or replace diseased cells, tissues and organs, and to cure diseases. Where appropriate, both CCRM Australia and BioCurate will support each other’s programmes to train the next wave of entrepreneurs on the business of regenerative medicine.

CCRM Australia’s CEO Silvio Tiziani noted, “CCRM Australia is thrilled to be working with the BioCurate team to support Australia’s growing regenerative medicine industry.  It is clear that the development of regenerative medicine has come of age and with many therapies currently in and coming out of clinical trials, it is critical for Australia to translate its strong research pipeline and add to this new wave of life changing therapies.”

 BioCurate’s CEO Dr Glenn Begley stated, “The boundary of medicines has yet again shifted beyond pharmaceutical drugs and biologics to include cellular therapies and gene therapies. Furthermore, the meteoric rise of CAR-T cancer immunotherapies has inevitably attracted clinical as well as investment interests. BioCurate’s collaboration with CCRM Australia is a critical step to accelerate the translation of innovative regenerative medicine research into the healthcare market.”

The signing of the MoU brings together leaders in drug, biologic, regenerative medicine and medical technology development to pave a viable translation and commercialisation pathway for the Australian regenerative medicine sector.

 


 

About CCRM Australia

CCRM Australia is an Australian not-for-profit organisation supporting the development of foundational technologies to accelerate the commercialisation of regenerative medicine products and therapies. CCRM Australia’s focus is to bridge the commercialisation gap through a network of scientists, entrepreneurs, academic institutions and industry partners and address bottlenecks in the industry. CCRM Australia is modelled on the highly successful CCRM in Canada and is legally separate to CCRM. As a member of the Global CCRM network, CCRM Australia is a partner to a leading-edge industry consortium. CCRM Australia is supported by MTPConnect and the Victorian State Government.

Twitter: @CCRM_au

LinkedIn: https://www.linkedin.com/company/ccrm-australia/

 


 

About BioCurate

BioCurate Pty Ltd was formed jointly in June 2016 by The University of Melbourne and Monash University, with support from the Victorian State Government to accelerate early phases of new drug development. BioCurate is seeking to address the key challenges in early stage drug development and to increase the number, quality and rate of translation of new drug discoveries into medically sound projects that are attractive for investment via commercial or public-good routes. The Company’s vision is to be a recognised global leader in the translation of basic medical research into human therapeutics. For more information, please visit http://www.biocurate.com

Twitter: @biocurate

LinkedIn: https://www.linkedin.com/company/biocurate/

 


 

Media contacts

CCRM Australia: Dr Chih Wei Teng                           chihwei.teng@ccrmaustralia.com.au

BioCurate: Dr Damien Bates                                      d.bates@biocurate.com

 

Return to News
Share

Australia’s Brain Drain is ‘Good for Science’

Australia’s Brain Drain is ‘Good for Science’

Author

Date

David Swan, The Australian

June 26, 2019

Australia needs to become more comfortable with its talent leaving, according to the boss of one of the country’s leading biomedical research companies BioCurate.

C Glenn Begley is the CEO of BioCurate, an independently operated joint venture of the University of Melbourne and Monash University, and supported by the Victorian state government.

Much gets made of the ‘brain drain’ of science and technology talent deserting Australia for places like Silicon Valley, but according to Dr Begley, Australia has never had a ‘brain drain’. He said our best and brightest leaving Australia is, in fact, a good thing for science.

“What I would like to see happen is that people who have gained 15 to 20 years experience overseas start coming back to Australia, and bringing all that learning with them,” he said. “They bring that learning but also key contacts with them as well.”

Read more here: https://www.theaustralian.com.au/business/technology/australias-brain-drain-is-good-for-science/news-story/48cbfd1e0bed9b88449207fe2c95c22e

 

Return to News
Share

New Staff Appointment – Dr Damien Bates joins BioCurate

New Staff Appointment – Dr Damien Bates joins BioCurate

Author

Date

BioCurate

May 16, 2019

We are very pleased to advise that BioCurate has appointed Dr Damien Bates into the role of Chief Scientific Officer - Head of Translational Medicine.

Dr Bates is a senior healthcare industry executive specialising in global preclinical and clinical development, medical affairs, marketing authorisation and lifecycle management of biologics and devices. Damien has extensive international clinical and scientific experience with a proven track record in the successful execution of preclinical development programs, clinical trials and post-marketing medical support for approved and cleared products, and FDA, EMA, PMDA and SwissMedic negotiation & approvals.

Damien brings around 15 years of international experience in the health and industry sector and provides BioCurate with additional and complementary scientific expertise in the biology of regeneration, development, stem cells, neuroscience, angiogenesis, tissue engineering and transplantation immunology.

We are delighted Damien has decided to join the BioCurate team.

Click here to read more about Damien.

 

Return to News
Share

Biomedical Translation Bridge Program information sessions launch

Biomedical Translation Bridge Program information sessions launch

Author

Date

BioCurate

May 10, 2019

The Biomedical Translation Bridge (BTB) Program is an initiative of the Medical Research Future Fund, providing up to $1 million in matching funding to nurture the translation of new therapies, technologies and medical devices through to the proof of concept stage. The BTB program is operated by MTPConnect in partnership with BioCurate, UniQuest, the Medical Device Partnering Program and the Bridge and BridgeTech programs.

A national program of information sessions will be launched in Melbourne on Monday 13 May 2019. Join BioCurate CEO Dr C. Glenn Begley and representatives from MTPConnect, UniQuest, the Medical Device Partnering Program and the Bridge and BridgeTech programs to find out if the BTB Program could support your life sciences innovation.

For more information about the national program of information sessions, email danielle.shand@mtpconnect.org.au or keep an eye out on the MTPConnect website.

Click here to register for the Melbourne information session.

 

Return to News
Share